<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032704</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-005</org_study_id>
    <nct_id>NCT04032704</nct_id>
  </id_info>
  <brief_title>A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors</brief_title>
  <official_title>Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different
      types of solid tumors. It will also find out what side effects may occur. A side effect is
      anything the drug does besides treating cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is designed to assess the antitumor activity, safety, and tolerability of LV for
      the treatment of solid tumors. Participants with the following advanced solid tumors will be
      enrolled:

      Cohort 1: small cell lung cancer (SCLC) Cohort 2: non-small cell lung cancer-squamous
      (NSCLC-squamous) Cohort 3: non-small cell lung cancer-nonsquamous (NSCLC-nonsquamous) Cohort
      4: head and neck squamous cell carcinoma (HNSCC) Cohort 5: esophageal squamous cell carcinoma
      (esophageal-squamous) Cohort 6: gastric and gastroesophageal junction (GEJ) adenocarcinoma

      Participants will continue to receive study treatment until disease progression, unacceptable
      toxicity, investigator decision, consent withdrawal, study termination by the sponsor,
      pregnancy, or death, whichever comes first.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (ORR) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Confirmed ORR is defined as the proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>DCR is defined as the proportion of participants who achieve a confirmed CR or PR, or meet the stable disease (SD) criteria at least once after start of study treatment at a minimum interval of 5 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as determined by investigator according to RECIST v1.1</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>OS is defined as the time from the start of study treatment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>Pharmacokinetic (PK) endpoint of LV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
    <description>PK endpoint of LV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies (ATAs) to LV</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Non-small Cell Lung Cancer, Squamous</condition>
  <condition>Non-small Cell Lung Cancer, Non-squamous</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Ladiratuzumab Vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-LIV1A monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ladiratuzumab vedotin</intervention_name>
    <description>Intravenous (into the vein; IV) infusion</description>
    <arm_group_label>Ladiratuzumab Vedotin</arm_group_label>
    <other_name>SGN-LIV1A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  All Cohorts

               -  Measurable disease according to RECIST v1.1 as assessed by the investigator

               -  Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1

          -  Cohort 1: SCLC

               -  Must have extensive stage disease

               -  Must have disease progression during or following prior platinum-based systemic
                  chemotherapy for extensive stage disease;

               -  No more than 1 prior line of cytotoxic chemotherapy for extensive disease stage

               -  No more than 1 prior line of cytotoxic chemotherapy for extensive disease stage

               -  May have received prior anti-PD(L)1 therapy

          -  Cohort 2: NSCLC-squamous

               -  Must have unresectable locally advanced or metastatic disease

               -  Must have disease progression during or following systemic therapy

                    -  Participants must have progressed during or after a platinum-based
                       combination therapy administered for the treatment of metastatic disease, OR

                    -  Participants must have progressed within 6 months of last dose of
                       platinum-based adjuvant, neoadjuvant, or definitive chemotherapy, or
                       concomitant chemoradiation regimen for early stage or locally advanced stage
                       disease.

               -  Participants with known epidermal growth factor receptor (EGFR), anaplastic
                  lymphoma kinase (ALK), reactive oxygen species (ROS), BRAF, or other actionable
                  mutations are not eligible

               -  No more than 1 prior line of cytotoxic chemotherapy for their advanced disease

               -  Must have received prior anti-PD(L)1 therapy, unless contraindicated

          -  Cohort 3: NSCLC-nonsquamous

               -  Must have unresectable locally advanced or metastatic disease

               -  Must have disease progression during or following systemic therapy

                    -  Participants must have progressed during or after a platinum-based
                       combination therapy administered for the treatment of metastatic disease, OR

                    -  Participants must have progressed within 6 months of last dose of
                       platinum-based adjuvant, neoadjuvant, or definitive chemotherapy, or
                       concomitant chemoradiation regimen for early stage or locally advanced state
                       disease.

               -  Participants with known EGFR, ALK, ROS, BRAF, tropomyosin receptor kinase (TRK),
                  or other actionable mutations are not eligible

               -  Must have had prior platinum-based chemotherapy

               -  No more than 1 prior line of cytotoxic chemotherapy for their advanced disease

               -  Must have received prior anti-PD(L)1 therapy, unless contraindicated

          -  Cohort 4: HNSCC

               -  Must have unresectable locally recurrent or metastatic disease

                    -  Must have disease progression during or following prior line of systemic
                       therapy

                    -  Disease progression after treatment with a platinum-containing regimen for
                       recurrent/metastatic disease; or

                    -  Recurrence/progression within 6 months of last dose of platinum therapy
                       given as part of a multimodal therapy in the curative setting

               -  No more than 1 line of cytotoxic chemotherapy for their advanced disease

               -  May have received prior anti-PD(L)1 therapy, unless contraindicated

          -  Cohort 5: esophageal-squamous

               -  Must have unresectable locally advanced or metastatic disease

               -  Must have disease progression during or following systemic therapy

               -  Must have had prior platinum-based chemotherapy

               -  No more than 1 line of cytotoxic chemotherapy for their advanced disease

          -  Cohort 6: gastric and GEJ adenocarcinoma

               -  Must have unresectable locally advanced or metastatic disease

               -  Must have received prior platinum-based therapy

               -  Must have disease progression during or following systemic therapy

               -  Participants with known human epidermal growth factor receptor 2 (HER2)
                  overexpression must have received prior HER2-targeted therapy

               -  No more than 1 line of prior cytotoxic chemotherapy for their advanced disease

               -  Participants may have received prior anti-PD(L)1 therapy, unless contraindicated

        Exclusion Criteria

          -  Active concurrent malignancy or a previous malignancy within the past 3 years

          -  Any anticancer therapy within 3 weeks of starting study treatment. Participants who
             are/were on adjuvant hormonal therapy for the treatment of malignancies with
             negligible risk of metastases are eligible.

          -  Known active central nervous system lesions

          -  Active viral, bacterial, or fungal infection requiring systemic treatment within 7
             days prior to the first dose of LV

          -  Any ongoing clinically significant toxicity associated with prior treatment (Grade 2
             or higher)

          -  Ongoing sensory or motor neuropathy of Grade â‰¥2

          -  Documented history of a cerebral vascular event (stroke or transient ischemic attack),
             unstable angina, myocardial infarction, or cardiac symptoms consistent with congestive
             heart failure

          -  Has received prior radiotherapy within 2 weeks of start of study treatment

          -  Has received a live vaccine within 30 days of the planned start of study therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zejing Wang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Adventist Health White Memorial</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Montero</last_name>
      <phone>323-268-5000</phone>
      <email>monterhe@ah.org</email>
    </contact>
    <investigator>
      <last_name>Raymundo Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Heritage Medical Group</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Lund</last_name>
      <phone>707-521-3814</phone>
      <email>Teresa.lund@stjoe.org</email>
    </contact>
    <investigator>
      <last_name>Ian Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tambree Chapman</last_name>
      <phone>860-886-8362</phone>
      <email>tchapman@echoct.com</email>
    </contact>
    <investigator>
      <last_name>Dennis Slater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Novella</last_name>
      <phone>239-938-9315</phone>
      <email>rachel.novella@21co.com</email>
    </contact>
    <investigator>
      <last_name>Troy Guthrie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Scott</last_name>
      <phone>888-737-7408</phone>
      <email>gscott@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Pippas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joann Alimurong</last_name>
      <phone>410-328-2703</phone>
      <email>joann.alimurong@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Ranee Mehra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Schroeder</last_name>
      <phone>734-647-9437</phone>
      <email>morrowam@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Swiecicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-7263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Fidnarick</last_name>
      <phone>631-444-3577</phone>
      <email>Cara.Fidnarick@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Amna Sher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth of the Carolinas</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Williams</last_name>
      <phone>910-715-1922</phone>
      <email>jcwilliams@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Charles Kuzma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research, LLC</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith</last_name>
      <phone>330-492-3345 x208</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lopez</last_name>
      <phone>503-215-5696</phone>
      <email>canrsrchstudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Rachel Sanborn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital / Bon Secours - South Carolina</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Smith</last_name>
      <phone>864-603-6220</phone>
      <email>Gina_Smith@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erlanger Oncology and Hematology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Metcalf</last_name>
      <phone>423-778-2982</phone>
      <email>Jill.Metcalf@erlanger.org</email>
    </contact>
    <investigator>
      <last_name>Robert (Matt) Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Salas</last_name>
      <phone>806-725-8000</phone>
      <email>ssalas@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Isaac Tafur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health East Texas Hope Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Loredo</last_name>
      <phone>903-592-6152</phone>
      <phone_ext>286</phone_ext>
      <email>Grace.Loredo@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>Arielle Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyndsey Deverman</last_name>
      <phone>608-263-1836</phone>
      <email>lyndsey.deverman@wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laboratory Inbox</last_name>
      <phone>608-263-5369</phone>
      <email>3plab@lists.medicine.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Justine Bruce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital</name>
      <address>
        <city>Hobart</city>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Louise Nott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DONG-A University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sung Yong Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>In-Jae Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Seok Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Do-Youn Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Jae Yong Cho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703/08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Suwon</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Byoung Young Shim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hyun Woo Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Wu-Chou Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Chia-Chi Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>July 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCLC</keyword>
  <keyword>NSCLC-squamous</keyword>
  <keyword>NSCLC-nonsquamous</keyword>
  <keyword>HNSCC</keyword>
  <keyword>GEJ adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

